OBrien Christopher Flint 4
4 · NEUROCRINE BIOSCIENCES INC · Filed Jul 31, 2017
Insider Transaction Report
Form 4
OBrien Christopher Flint
Sr. VP & Chief Medical Officer
Transactions
- Exercise/Conversion
Common Stock
2017-07-27$8.65/sh+8,734$75,549→ 57,707 total - Exercise/Conversion
Non-Qualified Stock Option
2017-07-27$8.65/sh−8,734$75,549→ 77,266 totalExercise: $8.65Exp: 2023-01-10→ Common Stock (8,734 underlying) - Sale
Common Stock
2017-07-27$50.00/sh−8,734$436,700→ 48,973 total
Footnotes (2)
- [F1]The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
- [F2]Option granted January 10, 2013 and vested over 4 years.